跳至主要内容
临床试验/NCT01704937
NCT01704937已完成1 期

Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Safety

研究概览

简要总结

Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of a frozen inoculum administered by nasogastric tube vs administered by colonoscope.

Subjects with recurrent/relapsing C. difficile infection (10 per group) will receive FMT via either:

  • colonoscopy
  • NGT

The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
7 Years 至 90 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with recurrent or relapsing CDI defined as EITHER(13):
  • At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g. rifaximin, nitazoxanide).
  • At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.
  • Willingness to accept risk of unrelated donor stool
  • Willingness to be randomized to NGT vs. colonoscopic delivery.
  • Able to consent for self, or parental assent/child assent as age appropriate.

排除标准

  • Anatomic contraindication to NGT
  • Delayed gastric emptying syndrome
  • Known chronic aspiration
  • Contraindication to colonoscopy (ASA 4 or more)
  • High risk of bacterial translocation (Immunosuppression, cirrhosis etc)
  • Pregnant or breastfeeding women
  • Acute unrelated infection or comorbid illness exaccerbation

研究组 & 干预措施

Colonoscopy

Experimental

Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via colonoscopy

干预措施: Fecal Microbiota Transplant (FMT) (Drug)

Nasogastric Tube (NGT)

Experimental

Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via NGT

干预措施: Fecal Microbiota Transplant (FMT) (Drug)

结局指标

主要结局

Safety

时间窗: up to 6 mo post FMT

Safety is assessed by clinical symptoms, exam, signs (GI and systemic)

次要结局

  • Efficacy(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elizabeth L. Hohmann, MD

Principal Investigator

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验